{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:33Z","timestamp":1790957553360,"version":"4.1.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS107596"],"award-info":[{"award-number":["R01NS107596"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Auton Res"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10286-024-01016-5","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T06:02:16Z","timestamp":1706853736000},"page":"31-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Muscarinic control of cardiovascular function in humans: a review of current clinical evidence"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1345-6774","authenticated-orcid":false,"given":"Jose-Alberto","family":"Palma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"1016_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nn992","volume":"6","author":"SG Anagnostaras","year":"2003","unstructured":"Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6:51\u201358","journal-title":"Nat Neurosci"},{"key":"1016_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1365-2125.2008.03194.x","volume":"66","author":"TM Attina","year":"2008","unstructured":"Attina TM, Oliver JJ, Malatino LS, Webb DJ (2008) Contribution of the M3 muscarinic receptors to the vasodilator response to acetylcholine in the human forearm vascular bed. Br J Clin Pharmacol 66:300\u2013303","journal-title":"Br J Clin Pharmacol"},{"key":"1016_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004070","author":"M Awad","year":"2016","unstructured":"Awad M, Czer LS, Hou M, Golshani SS, Goltche M, De Robertis M, Kittleson M, Patel J, Azarbal B, Kransdorf E, Esmailian F, Trento A, Kobashigawa JA (2016) Early denervation and later reinnervation of the heart following cardiac transplantation: a review. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.116.004070","journal-title":"J Am Heart Assoc"},{"key":"1016_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13195-021-00816-5","volume":"13","author":"C Bakker","year":"2021","unstructured":"Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Doll RJ, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Cross DM, Groeneveld GJ, Nathan PJ (2021) Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M(1) receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study. Alzheimers Res Ther 13:87","journal-title":"Alzheimers Res Ther"},{"key":"1016_CR5","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1111\/bcp.14710","volume":"87","author":"C Bakker","year":"2021","unstructured":"Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Prins S, van der Doef TF, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Cross DM, Groeneveld GJ, Nathan PJ (2021) First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M(1) -receptor partial agonist for the treatment of dementias. Br J Clin Pharmacol 87:2945\u20132955","journal-title":"Br J Clin Pharmacol"},{"key":"1016_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/cge.13631","volume":"96","author":"GM Beaman","year":"2019","unstructured":"Beaman GM, Galata G, Teik KW, Urquhart JE, Aishah A, O\u2019Sullivan J, Bhaskar SS, Wood KA, Thomas HB, O\u2019Keefe RT, Woolf AS, Stuart HM, Newman WG (2019) A homozygous missense variant in CHRM3 associated with familial urinary bladder disease. Clin Genet 96:515\u2013520","journal-title":"Clin Genet"},{"key":"1016_CR7","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1021\/acschemneuro.8b00481","volume":"10","author":"AM Bender","year":"2019","unstructured":"Bender AM, Garrison AT, Lindsley CW (2019) The muscarinic acetylcholine receptor M(5): therapeutic implications and allosteric modulation. ACS Chem Neurosci 10:1025\u20131034","journal-title":"ACS Chem Neurosci"},{"key":"1016_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","volume":"54","author":"NC Bodick","year":"1997","unstructured":"Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54:465\u2013473","journal-title":"Arch Neurol"},{"key":"1016_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/cpdd.732","volume":"9","author":"MT Borin","year":"2020","unstructured":"Borin MT, Barnes CN, Darpo B, Pendyala S, Xue H, Bourdet DL (2020) Revefenacin, a long-acting muscarinic antagonist, does not prolong QT interval in healthy subjects: results of a placebo- and positive-controlled thorough QT study. Clin Pharmacol Drug Dev 9:130\u2013139","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1016_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A (2021) Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med 384:717\u2013726","journal-title":"N Engl J Med"},{"key":"1016_CR11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s003950170003","volume":"96","author":"OE Brodde","year":"2001","unstructured":"Brodde OE, Bruck H, Leineweber K, Seyfarth T (2001) Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res Cardiol 96:528\u2013538","journal-title":"Basic Res Cardiol"},{"issue":"5886\u20135901","key":"1016_CR12","first-page":"e5822","volume":"184","author":"AJH Brown","year":"2021","unstructured":"Brown AJH, Bradley SJ, Marshall FH, Brown GA, Bennett KA, Brown J, Cansfield JE, Cross DM, de Graaf C, Hudson BD, Dwomoh L, Dias JM, Errey JC, Hurrell E, Liptrot J, Mattedi G, Molloy C, Nathan PJ, Okrasa K, Osborne G, Patel JC, Pickworth M, Robertson N, Shahabi S, Bundgaard C, Phillips K, Broad LM, Goonawardena AV, Morairty SR, Browning M, Perini F, Dawson GR, Deakin JFW, Smith RT, Sexton PM, Warneck J, Vinson M, Tasker T, Tehan BG, Teobald B, Christopoulos A, Langmead CJ, Jazayeri A, Cooke RM, Rucktooa P, Congreve MS, Weir M, Tobin AB (2021) From structure to clinic: design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer\u2019s disease. Cell 184(5886\u20135901):e5822","journal-title":"Cell"},{"key":"1016_CR13","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/S0024-3205(01)01041-4","volume":"68","author":"FP Bymaster","year":"2001","unstructured":"Bymaster FP, Carter PA, Zhang L, Falcone JF, Stengel PW, Cohen ML, Shannon HE, Gomeza J, Wess J, Felder CC (2001) Investigations into the physiological role of muscarinic M2 and M4 muscarinic and M4 receptor subtypes using receptor knockout mice. Life Sci 68:2473\u20132479","journal-title":"Life Sci"},{"key":"1016_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1213\/00000539-197503000-00027","volume":"54","author":"DJ Carrow","year":"1975","unstructured":"Carrow DJ, Aldrete JA, Masden RR, Jackson D (1975) Effects of large doses of intravenous atropine on heart rate and arterial pressure of anesthetized patients. Anesth Analg 54:262\u2013266","journal-title":"Anesth Analg"},{"key":"1016_CR15","unstructured":"Cerevel (2022) Cerevel Therapeutics announces positive results in emraclidine ambulatory blood pressure monitoring trial (press release). https:\/\/investors.cerevel.com\/news-releases\/news-release-details\/cerevel-therapeutics-announces-positive-results-emraclidine\/"},{"key":"1016_CR16","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/01.RES.85.12.1214","volume":"85","author":"FM Faraci","year":"1999","unstructured":"Faraci FM, Sigmund CD (1999) Vascular biology in genetically altered mice: smaller vessels, bigger insight. Circ Res 85:1214\u20131225","journal-title":"Circ Res"},{"key":"1016_CR17","first-page":"154","volume":"6","author":"GT Ferguson","year":"2019","unstructured":"Ferguson GT, Feldman G, Pudi KK, Barnes CN, Moran EJ, Haumann B, Pendyala S, Crater G (2019) Improvements in lung function with nebulized revefenacin in the treatment of patients with moderate to very severe COPD: results from two replicate phase\u00a0III clinical trials. Chronic Obstr Pulm Dis 6:154\u2013165","journal-title":"Chronic Obstr Pulm Dis"},{"key":"1016_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1749-6632.1996.tb34418.x","volume":"777","author":"A Fisher","year":"1996","unstructured":"Fisher A, Heldman E, Gurwitz D, Haring R, Karton Y, Meshulam H, Pittel Z, Marciano D, Brandeis R, Sadot E, Barg Y, Pinkas-Kramarski R, Vogel Z, Ginzburg I, Treves TA, Verchovsky R, Klimowsky S, Korczyn AD (1996) M1 agonists for the treatment of Alzheimer\u2019s disease. Novel properties and clinical update. Ann N Y Acad Sci 777:189\u2013196","journal-title":"Ann N Y Acad Sci"},{"key":"1016_CR19","first-page":"25","volume":"139","author":"BV Franko","year":"1963","unstructured":"Franko BV, Ward JW, Alphin RS (1963) Pharmacologic studies of N-benzyl-3-pyrrolidyl acetate methobromide (AHR-602), a ganglion stimulating agent. J Pharmacol Exp Ther 139:25\u201330","journal-title":"J Pharmacol Exp Ther"},{"key":"1016_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1124\/jpet.117.246991","volume":"365","author":"RG Gogliotti","year":"2018","unstructured":"Gogliotti RG, Fisher NM, Stansley BJ, Jones CK, Lindsley CW, Conn PJ, Niswender CM (2018) Total RNA sequencing of Rett syndrome autopsy samples identifies the M(4) muscarinic receptor as a novel therapeutic target. J Pharmacol Exp Ther 365:291\u2013300","journal-title":"J Pharmacol Exp Ther"},{"key":"1016_CR21","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1073\/pnas.96.4.1692","volume":"96","author":"J Gomeza","year":"1999","unstructured":"Gomeza J, Shannon H, Kostenis E, Felder C, Zhang L, Brodkin J, Grinberg A, Sheng H, Wess J (1999) Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Nat Acad Sci U S A 96:1692\u20131697","journal-title":"Proc Nat Acad Sci U S A"},{"key":"1016_CR22","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/S0024-3205(01)01039-6","volume":"68","author":"J Gomeza","year":"2001","unstructured":"Gomeza J, Zhang L, Kostenis E, Felder CC, Bymaster FP, Brodkin J, Shannon H, Xia B, Duttaroy A, Deng CX, Wess J (2001) Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice. Life Sci 68:2457\u20132466","journal-title":"Life Sci"},{"key":"1016_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1124\/jpet.301.1.129","volume":"301","author":"SN Hardouin","year":"2002","unstructured":"Hardouin SN, Richmond KN, Zimmerman A, Hamilton SE, Feigl EO, Nathanson NM (2002) Altered cardiovascular responses in mice lacking the M(1) muscarinic acetylcholine receptor. J Pharmacol Exp Ther 301:129\u2013137","journal-title":"J Pharmacol Exp Ther"},{"key":"1016_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-23274-9_13","author":"RD Harvey","year":"2012","unstructured":"Harvey RD (2012) Muscarinic receptor agonists and antagonists: effects on cardiovascular function. Handb Exp Pharmacol. https:\/\/doi.org\/10.1007\/978-3-642-23274-9_13","journal-title":"Handb Exp Pharmacol"},{"key":"1016_CR25","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/sj.bjp.0705338","volume":"139","author":"RD Harvey","year":"2003","unstructured":"Harvey RD, Belevych AE (2003) Muscarinic regulation of cardiac ion channels. Br J Pharmacol 139:1074\u20131084","journal-title":"Br J Pharmacol"},{"key":"1016_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11255-015-0916-1","volume":"47","author":"W Huang","year":"2015","unstructured":"Huang W, Zong H, Zhou X, Zhang Y (2015) Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis. Int Urol Nephrol 47:457\u2013464","journal-title":"Int Urol Nephrol"},{"key":"1016_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1161\/01.RES.65.2.237","volume":"65","author":"S Kalsner","year":"1989","unstructured":"Kalsner S (1989) Cholinergic constriction in the general circulation and its role in coronary artery spasm. Circ Res 65:237\u2013257","journal-title":"Circ Res"},{"key":"1016_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2023","unstructured":"Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK (2023) Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase\u00a03 trial. Lancet 403:160","journal-title":"Lancet"},{"key":"1016_CR29","unstructured":"Kavoussi R, Miller A, Brannan S, Breier A (2017) Results of a double-blind, placebo-controlled, tolerability study of KarXT, a novel combination targeting muscarinic acetylcholine receptors using xanomeline with trospium chloride to mitigate cholinergic side effects. In: Poster presented at American Society of Clinical Psychopharmacology Annual Meeting, Miami Beach, FL, May 29\u2013June 2, 2017"},{"key":"1016_CR30","first-page":"92","volume":"57","author":"F Kobayashi","year":"2007","unstructured":"Kobayashi F, Yageta Y, Segawa M, Matsuzawa S (2007) Effects of imidafenacin (KRP-197\/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 57:92\u2013100","journal-title":"Arzneimittelforschung"},{"key":"1016_CR31","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1517\/13543784.9.10.2259","volume":"9","author":"AD Korczyn","year":"2000","unstructured":"Korczyn AD (2000) Muscarinic M(1) agonists in the treatment of Alzheimer\u2019s disease. Expert Opin Investig Drugs 9:2259\u20132267","journal-title":"Expert Opin Investig Drugs"},{"key":"1016_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrd4295","volume":"13","author":"AC Kruse","year":"2014","unstructured":"Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, Wess J (2014) Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov 13:549\u2013560","journal-title":"Nat Rev Drug Discov"},{"key":"1016_CR33","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","volume":"400","author":"JH Krystal","year":"2022","unstructured":"Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, Patel S, Chang I, Iredale P, Frohlich L, Versavel S, Perry P, Sanchez R, Renger J (2022) Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase\u00a01b trial. Lancet 400:2210\u20132220","journal-title":"Lancet"},{"key":"1016_CR34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1113\/jphysiol.2003.052449","volume":"553","author":"SG Lechner","year":"2003","unstructured":"Lechner SG, Mayer M, Boehm S (2003) Activation of M1 muscarinic receptors triggers transmitter release from rat sympathetic neurons through an inhibition of M-type K+ channels. J Physiol 553:789\u2013802","journal-title":"J Physiol"},{"key":"1016_CR35","doi-asserted-by":"publisher","first-page":"e01040","DOI":"10.1002\/prp2.1040","volume":"11","author":"DY Lee","year":"2023","unstructured":"Lee DY, Lee MJ, Ryu C, Lee H, Brooks A (2023) Safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of DA-8010 in healthy subjects: first-in-human phase\u00a0I study. Pharmacol Res Perspect 11:e01040","journal-title":"Pharmacol Res Perspect"},{"key":"1016_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/17512433.2019.1587292","volume":"12","author":"F Li","year":"2019","unstructured":"Li F, Yang J (2019) Revefenacin for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol 12:293\u2013298","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1016_CR37","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1080\/15563650903008448","volume":"47","author":"Y Lurie","year":"2009","unstructured":"Lurie Y, Wasser SP, Taha M, Shehade H, Nijim J, Hoffmann Y, Basis F, Vardi M, Lavon O, Suaed S, Bisharat B, Bentur Y (2009) Mushroom poisoning from species of genus Inocybe (fiber head mushroom): a case series with exact species identification. Clin Toxicol (Phila) 47:562\u2013565","journal-title":"Clin Toxicol (Phila)"},{"key":"1016_CR38","unstructured":"MapLight (2023) MapLight Therapeutics announces successful completion of second phase\u00a01 clinical trial of the novel muscarinic receptor agonist ML-007 (press release). https:\/\/maplightrx.com\/agonist-ml-007\/"},{"key":"1016_CR39","doi-asserted-by":"publisher","first-page":"9579","DOI":"10.1073\/pnas.97.17.9579","volume":"97","author":"M Matsui","year":"2000","unstructured":"Matsui M, Motomura D, Karasawa H, Fujikawa T, Jiang J, Komiya Y, Takahashi S, Taketo MM (2000) Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Nat Acad Sci U S A 97:9579\u20139584","journal-title":"Proc Nat Acad Sci U S A"},{"key":"1016_CR40","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/01.HYP.29.3.828","volume":"29","author":"A Medina","year":"1997","unstructured":"Medina A, Bodick N, Goldberger AL, Mac Mahon M, Lipsitz LA (1997) Effects of central muscarinic-1 receptor stimulation on blood pressure regulation. Hypertension 29:828\u2013834","journal-title":"Hypertension"},{"key":"1016_CR41","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1017\/S1461145712000752","volume":"16","author":"PJ Nathan","year":"2013","unstructured":"Nathan PJ, Watson J, Lund J, Davies CH, Peters G, Dodds CM, Swirski B, Lawrence P, Bentley GD, O\u2019Neill BV, Robertson J, Watson S, Jones GA, Maruff P, Croft RJ, Laruelle M, Bullmore ET (2013) The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol 16:721\u2013731","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2231\u20132247","key":"1016_CR42","first-page":"e2237","volume":"24","author":"Y Niwa","year":"2018","unstructured":"Niwa Y, Kanda GN, Yamada RG, Shi S, Sunagawa GA, Ukai-Tadenuma M, Fujishima H, Matsumoto N, Masumoto KH, Nagano M, Kasukawa T, Galloway J, Perrin D, Shigeyoshi Y, Ukai H, Kiyonari H, Sumiyama K, Ueda HR (2018) Muscarinic acetylcholine receptors Chrm1 and Chrm3 are essential for REM sleep. Cell Rep 24(2231\u20132247):e2237","journal-title":"Cell Rep"},{"key":"1016_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1476-5381.1996.tb15688.x","volume":"119","author":"X Norel","year":"1996","unstructured":"Norel X, Walch L, Costantino M, Labat C, Gorenne I, Dulmet E, Rossi F, Brink C (1996) M1 and M3 muscarinic receptors in human pulmonary arteries. Br J Pharmacol 119:149\u2013157","journal-title":"Br J Pharmacol"},{"key":"1016_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1124\/jpet.121.000709","volume":"379","author":"R Okimoto","year":"2021","unstructured":"Okimoto R, Ino K, Ishizu K, Takamatsu H, Sakamoto K, Yuyama H, Fuji H, Someya A, Ohtake A, Ishigami T, Masuda N, Takeda M, Kajioka S, Yoshimura N (2021) Potentiation of muscarinic M(3) receptor activation through a new allosteric site with a novel positive allosteric modulator ASP8302. J Pharmacol Exp Ther 379:64\u201373","journal-title":"J Pharmacol Exp Ther"},{"key":"1016_CR45","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1212\/WNL.0000000000000605","volume":"83","author":"JA Palma","year":"2014","unstructured":"Palma JA, Benarroch EE (2014) Neural control of the heart: recent concepts and clinical correlations. Neurology 83:261\u2013271","journal-title":"Neurology"},{"key":"1016_CR46","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/ana.25882","volume":"88","author":"JA Palma","year":"2020","unstructured":"Palma JA, Gupta A, Sierra S, Gomes I, Balgobin B, Norcliffe-Kaufmann L, Devi LA, Kaufmann H (2020) Autoantibodies blocking M(3) muscarinic receptors cause postganglionic cholinergic dysautonomia. Ann Neurol 88:1237\u20131243","journal-title":"Ann Neurol"},{"key":"1016_CR47","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/mds.27344","volume":"33","author":"JA Palma","year":"2018","unstructured":"Palma JA, Kaufmann H (2018) Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord 33:372\u2013390","journal-title":"Mov Disord"},{"key":"1016_CR48","doi-asserted-by":"publisher","first-page":"e008587","DOI":"10.1161\/CIRCINTERVENTIONS.119.008587","volume":"13","author":"VS Pargaonkar","year":"2020","unstructured":"Pargaonkar VS, Lee JH, Chow EKH, Nishi T, Ball RL, Kobayashi Y, Kimura T, Lee DP, Stefanick ML, Fearon WF, Yeung AC, Tremmel JA (2020) Dose-response relationship between intracoronary acetylcholine and minimal lumen diameter in coronary endothelial function testing of women and men with angina and no obstructive coronary artery disease. Circ Cardiovasc Interv 13:e008587","journal-title":"Circ Cardiovasc Interv"},{"key":"1016_CR49","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.phrs.2006.07.001","volume":"54","author":"CC Perez","year":"2006","unstructured":"Perez CC, Tobar ID, Jimenez E, Castaneda D, Rivero MB, Concepcion JL, Chiurillo MA, Bonfante-Cabarcas R (2006) Kinetic and molecular evidences that human cardiac muscle express non-M2 muscarinic receptor subtypes that are able to interact themselves. Pharmacol Res 54:345\u2013355","journal-title":"Pharmacol Res"},{"key":"1016_CR50","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1212\/WNL.0b013e31820a0a75","volume":"76","author":"JK Pomper","year":"2011","unstructured":"Pomper JK, Wilhelm H, Tayebati SK, Asmus F, Schule R, Sievert KD, Haensch CA, Melms A, Haarmeier T (2011) A novel clinical syndrome revealing a deficiency of the muscarinic M3 receptor. Neurology 76:451\u2013455","journal-title":"Neurology"},{"key":"1016_CR51","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12931-017-0647-1","volume":"18","author":"KK Pudi","year":"2017","unstructured":"Pudi KK, Barnes CN, Moran EJ, Haumann B, Kerwin E (2017) A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res 18:182","journal-title":"Respir Res"},{"key":"1016_CR52","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1124\/jpet.113.203554","volume":"346","author":"MT Pulido-Rios","year":"2013","unstructured":"Pulido-Rios MT, McNamara A, Obedencio GP, Ji Y, Jaw-Tsai S, Martin WJ, Hegde SS (2013) In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther 346:241\u2013250","journal-title":"J Pharmacol Exp Ther"},{"key":"1016_CR53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pupt.2017.10.003","volume":"48","author":"D Quinn","year":"2018","unstructured":"Quinn D, Barnes CN, Yates W, Bourdet DL, Moran EJ, Potgieter P, Nicholls A, Haumann B, Singh D (2018) Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): results of two randomized, double-blind, phase\u00a02 studies. Pulm Pharmacol Ther 48:71\u201379","journal-title":"Pulm Pharmacol Ther"},{"key":"1016_CR54","doi-asserted-by":"publisher","first-page":"e13262","DOI":"10.1111\/apha.13262","volume":"226","author":"A Rhoden","year":"2019","unstructured":"Rhoden A, Speiser J, Geertz B, Uebeler J, Schmidt K, de Wit C, Eschenhagen T (2019) Preserved cardiovascular homeostasis despite blunted acetylcholine-induced dilation in mice with endothelial muscarinic M3 receptor deletion. Acta Physiol (Oxf) 226:e13262","journal-title":"Acta Physiol (Oxf)"},{"key":"1016_CR55","first-page":"156","volume":"132","author":"AP Roszkowski","year":"1961","unstructured":"Roszkowski AP (1961) An unusual type of sympathetic ganglionic stimulant. J Pharmacol Exp Ther 132:156\u2013170","journal-title":"J Pharmacol Exp Ther"},{"key":"1016_CR56","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10286-013-0200-3","volume":"23","author":"R Sakakibara","year":"2013","unstructured":"Sakakibara R, Tateno F, Yano M, Takahashi O, Sugiyama M, Ogata T, Haruta H, Kishi M, Tsuyusaki Y, Yamamoto T, Uchiyama T, Yamanishi T, Yamaguchi C (2013) Imidafenacin on bladder and cognitive function in neurologic OAB patients. Clin Auton Res 23:189\u2013195","journal-title":"Clin Auton Res"},{"key":"1016_CR57","doi-asserted-by":"publisher","first-page":"e000227","DOI":"10.1161\/JAHA.113.000227","volume":"2","author":"K Sato","year":"2013","unstructured":"Sato K, Kaikita K, Nakayama N, Horio E, Yoshimura H, Ono T, Ohba K, Tsujita K, Kojima S, Tayama S, Hokimoto S, Matsui K, Sugiyama S, Yamabe H, Ogawa H (2013) Coronary vasomotor response to intracoronary acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive patients with coronary spasm: analysis of a single-center study over 20\u00a0years. J Am Heart Assoc 2:e000227","journal-title":"J Am Heart Assoc"},{"key":"1016_CR58","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/ajmg.a.63241","volume":"191","author":"S Schneider","year":"2023","unstructured":"Schneider S, Schierbaum L, Burger WAC, Seltzsam S, Wang C, Zheng B, Wu CW, Nakayama M, Connaughton DM, Mann N, Shalaby MA, Kari JA, ElDesoky S, Tasic V, Eid LA, Shril S, Thal DM, Hildebrandt F (2023) Recessive CHRM5 variant as a potential cause of neurogenic bladder. Am J Med Genet A 191:2083\u20132091","journal-title":"Am J Med Genet A"},{"key":"1016_CR59","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","volume":"165","author":"A Shekhar","year":"2008","unstructured":"Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165:1033\u20131039","journal-title":"Am J Psychiatry"},{"key":"1016_CR60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.5213\/inj.2142382.191","volume":"26","author":"HS Son","year":"2022","unstructured":"Son HS, Oh CY, Choo MS, Kim HG, Kim JC, Lee KS, Shin DG, Cho SY, Jeong SJ, Seo JT, Yoon H, Moon HS, Kim JH (2022) Efficacy and safety of DA-8010, a novel M3 antagonist, in patients with overactive bladder: a randomized, double-blind phase\u00a02 study. Int Neurourol J 26:119\u2013128","journal-title":"Int Neurourol J"},{"key":"1016_CR61","unstructured":"Sosei-Heptares (2022) Sosei Heptares\u2019 oral, selective M4 receptor agonist advancing into phase\u00a02 clinical development under multi-program collaboration with Neurocrine Biosciences (press release). https:\/\/soseiheptares.com\/news\/787\/129\/Sosei-Heptares-Oral-Selective-M4-Receptor-Agonist-Advancing-into-Phase-2-Clinical-Development-under-Multi-Program-Collaboration-with-Neurocrine-Biosciences.html"},{"key":"1016_CR62","first-page":"877","volume":"292","author":"PW Stengel","year":"2000","unstructured":"Stengel PW, Gomeza J, Wess J, Cohen ML (2000) M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther 292:877\u2013885","journal-title":"J Pharmacol Exp Ther"},{"key":"1016_CR63","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1021\/acschemneuro.9b00335","volume":"10","author":"CA Thorn","year":"2019","unstructured":"Thorn CA, Moon J, Bourbonais CA, Harms J, Edgerton JR, Stark E, Steyn SJ, Butler CR, Lazzaro JT, O\u2019Connor RE, Popiolek M (2019) Striatal, hippocampal, and cortical networks are differentially responsive to the M4- and M1-muscarinic acetylcholine receptor mediated effects of xanomeline. ACS Chem Neurosci 10:3910","journal-title":"ACS Chem Neurosci"},{"key":"1016_CR64","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Ponten F (2015) Proteomics. Tissue-based map of the human proteome. Science 347:1260419","journal-title":"Science"},{"key":"1016_CR65","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/nau.24931","volume":"41","author":"JWO van Till","year":"2022","unstructured":"van Till JWO, Arita E, Kuroishi K, Croy R, Oelke M, van Koeveringe GA, Chapple CR, Yamaguchi O, Abrams P (2022) Muscarinic-3-receptor positive allosteric modulator ASP8302 in patients with underactive bladder. A randomized controlled trial. Neurourol Urodyn 41:1139\u20131148","journal-title":"Neurourol Urodyn"},{"key":"1016_CR66","doi-asserted-by":"publisher","first-page":"e13273","DOI":"10.1111\/apha.13273","volume":"226","author":"PM Vanhoutte","year":"2019","unstructured":"Vanhoutte PM (2019) Endothelial muscarinic M(3)-receptors: a sigma-target? Acta Physiol (Oxf) 226:e13273","journal-title":"Acta Physiol (Oxf)"},{"key":"1016_CR67","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/apha.12646","volume":"219","author":"PM Vanhoutte","year":"2017","unstructured":"Vanhoutte PM, Shimokawa H, Feletou M, Tang EH (2017) Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf) 219:22\u201396","journal-title":"Acta Physiol (Oxf)"},{"key":"1016_CR68","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.trci.2018.03.004","volume":"4","author":"T Voss","year":"2018","unstructured":"Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, Leibensperger H, Snow-Adami L, McMahon KB, Egan M, Michelson D (2018) Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer\u2019s disease. Alzheimers Dement (N Y) 4:173\u2013181","journal-title":"Alzheimers Dement (N Y)"},{"key":"1016_CR69","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/sj.bjp.0703301","volume":"130","author":"L Walch","year":"2000","unstructured":"Walch L, Gascard JP, Dulmet E, Brink C, Norel X (2000) Evidence for a M(1) muscarinic receptor on the endothelium of human pulmonary veins. Br J Pharmacol 130:73\u201378","journal-title":"Br J Pharmacol"},{"key":"1016_CR70","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1124\/mol.59.5.1029","volume":"59","author":"H Wang","year":"2001","unstructured":"Wang H, Han H, Zhang L, Shi H, Schram G, Nattel S, Wang Z (2001) Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol Pharmacol 59:1029\u20131036","journal-title":"Mol Pharmacol"},{"key":"1016_CR71","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/sj.bjp.0705787","volume":"142","author":"Z Wang","year":"2004","unstructured":"Wang Z, Shi H, Wang H (2004) Functional M3 muscarinic acetylcholine receptors in mammalian hearts. Br J Pharmacol 142:395\u2013408","journal-title":"Br J Pharmacol"},{"key":"1016_CR72","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2165\/00003495-200868120-00006","volume":"68","author":"J Weber","year":"2008","unstructured":"Weber J, Keating GM (2008) Cevimeline. Drugs 68:1691\u20131698","journal-title":"Drugs"},{"key":"1016_CR73","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ajhg.2011.10.007","volume":"89","author":"S Weber","year":"2011","unstructured":"Weber S, Thiele H, Mir S, Toliat MR, Sozeri B, Reutter H, Draaken M, Ludwig M, Altmuller J, Frommolt P, Stuart HM, Ranjzad P, Hanley NA, Jennings R, Newman WG, Wilcox DT, Thiel U, Schlingmann KP, Beetz R, Hoyer PF, Konrad M, Schaefer F, Nurnberg P, Woolf AS (2011) Muscarinic acetylcholine receptor M3 mutation causes urinary bladder disease and a prune-belly-like syndrome. Am J Hum Genet 89:668\u2013674","journal-title":"Am J Hum Genet"},{"key":"1016_CR74","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrd2379","volume":"6","author":"J Wess","year":"2007","unstructured":"Wess J, Eglen RM, Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721\u2013733","journal-title":"Nat Rev Drug Discov"},{"key":"1016_CR75","doi-asserted-by":"publisher","first-page":"7267","DOI":"10.1113\/JP272927","volume":"594","author":"C Wilson","year":"2016","unstructured":"Wilson C, Lee MD, McCarron JG (2016) Acetylcholine released by endothelial cells facilitates flow-mediated dilatation. J Physiol 594:7267\u20137307","journal-title":"J Physiol"},{"key":"1016_CR76","doi-asserted-by":"publisher","first-page":"14096","DOI":"10.1073\/pnas.251542998","volume":"98","author":"M Yamada","year":"2001","unstructured":"Yamada M, Lamping KG, Duttaroy A, Zhang W, Cui Y, Bymaster FP, McKinzie DL, Felder CC, Deng CX, Faraci FM, Wess J (2001) Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A 98:14096\u201314101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1016_CR77","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/35065604","volume":"410","author":"M Yamada","year":"2001","unstructured":"Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, Makita R, Ogawa M, Chou CJ, Xia B, Crawley JN, Felder CC, Deng CX, Wess J (2001) Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 410:207\u2013212","journal-title":"Nature"},{"key":"1016_CR78","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bcp.14975","volume":"88","author":"W Yin","year":"2022","unstructured":"Yin W, Mamashli F, Buhl DL, Khudyakov P, Volfson D, Martenyi F, Gevorkyan H, Rosen L, Simen AA (2022) Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects. Br J Clin Pharmacol 88:600\u2013612","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Autonomic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-024-01016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10286-024-01016-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-024-01016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T17:04:28Z","timestamp":1710608668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10286-024-01016-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1016"],"URL":"https:\/\/doi.org\/10.1007\/s10286-024-01016-5","relation":{},"ISSN":["0959-9851","1619-1560"],"issn-type":[{"value":"0959-9851","type":"print"},{"value":"1619-1560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"10 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research funding from NIH. Salary from Eli Lilly and Co.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}